GHP June 2017

GHP / June 2017 25 Contact: Bob Harman Contact Email: [email protected] Company: VetStem Biopharma 12860 Danielson Court, Suite B Poway, CA 92064 Telephone: 858-748-2004 Web Address vetstem.com Leaders in the Use of Stem Cells to Treat Animals g medicine and bring immense value to the development and commercial efforts needed to launch veterinary cell therapy platform. To our knowledge, VetStem has constructed the first GMP (FDA Good Manufacturing Practices) manufacturing facility designed exclusively for animal health cell therapy products. This facility has produced multiple stem cell FDA registration batches that have been used in pivotal clinical and safety studies. The facility design is modular and we have the ability to expand manufacturing capabilities in a cost efficient manner as the demand for our products grow. In the veterinary regenerative medicine space, VetStem is the only company to have published multiple peer-reviewed papers from blinded placebo controlled clinical studies. We have declared it our mission to provide evidenced-based new products and services to veterinarians; the data speak volumes about the quality and dedication of the company and its employees. Also, we have provided nationally approved continuing education to over 5,000 practicing veterinarians in North America. The potential to modify the course of chronic diseases is the ultimate frontier and is the promise of cell therapy. This could significantly disrupt the market for established chemical-based drugs. NSAIDs for pain management are a perfect example of where such disruption could come in first. Painful osteoarthritis affects over 20% of senior pets – roughly 7M potential canine patients in the US today, for which NSAIDs are often the treatment of choice. Beyond the initial disruption, these therapies could also expand the market. For example, under-diagnosed joint issues affect millions of aging cats, and there are no long-term approved pain management drugs available for them. Cell therapy could be a viable option. The regulators in the US and Europe have made it clear that manufactured stem cell products are considered drugs and would require their approval. Due to the strong evidence of efficacy from autologous cell therapy, the first FDA approval of a veterinary cellular therapy will probably happen in the area of therapy for osteoarthritis. In the animal health industry, blockbusters (over $100M annual sales) are rare, and many segments with such potential are overly crowded. Cell therapy could birth many new blockbuster products (pain management, renal diseases, auto-immune diseases, diabetes to name a few) and open entirely new therapeutic segments in our industry. VetStem is growing and seeking additional funding and partnerships to leverage the last 14-years of experience, as well as our recent FDA development experience. We now seek additional funding for bringing a portfolio of additional Allo products to market for dogs, cats and horses. Once these products are near FDA approval, we will then license them to various veterinary companies that have already expressed a desire to market them in the US and abroad. VetStem is hopeful that the first FDA approval of our canine OA cell therapy product will occur in late 2018 or early 2019. VetStem will remain the manufacturer of these cell products and continue to provide a pipeline of innovative new stem cell products to the veterinary professions. Our revenue will consist of royalties, manufacturing margin, and development milestone payments. VetStem is proud to have been part of the birthing of this new segment of animal health. Alongside this, we have worked with our counterparts in human medicine to share data and experiences to move cell therapy towards clinical approval in human and veterinary medicine.